1. Home
  2. KTTA
  3. KTTA News

Latest Pasithea Therapeutics Corp. (KTTA) News on September 19, 2025

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
KTTA

GlobeNewswire

11 days ago

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
KTTA

GlobeNewswire

3 months ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
KTTA

GlobeNewswire

4 months ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
KTTA

GlobeNewswire

4 months ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
KTTA

Clinical Trials Arena

4 months ago

Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
KTTA

GlobeNewswire

4 months ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea Therapeutics Announces Closing of $5 Million Public Offering
KTTA

GlobeNewswire

4 months ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics 3.57M share Secondary priced at $1.40
KTTA

TipRanks

4 months ago

Pasithea Therapeutics 3.57M share Secondary priced at $1.40

KTTA

MT Newswires

4 months ago

Pasithea Therapeutics Prices $5 Million Public Offering

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering
KTTA

GlobeNewswire

4 months ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004
KTTA

GlobeNewswire

4 months ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients
KTTA

GlobeNewswire

5 months ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting
KTTA

GlobeNewswire

5 months ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

KTTA

MT Newswires

5 months ago

Top Midday Gainers

KTTA

MT Newswires

5 months ago

Sector Update: Health Care Stocks Drop Thursday Afternoon

KTTA

MT Newswires

5 months ago

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
KTTA

GlobeNewswire

5 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
KTTA

GlobeNewswire

6 months ago

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

KTTA

MT Newswires

7 months ago

Top Midday Gainers

KTTA

MT Newswires

7 months ago

Top Premarket Gainers

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
KTTA

GlobeNewswire

7 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
KTTA

GlobeNewswire

8 months ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
KTTA

GlobeNewswire

10 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

KTTA

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Late Afternoon

KTTA

MT Newswires

a year ago

Sector Update: Health Care

KTTA

MT Newswires

a year ago

Top Midday Gainers

Why Is Pasithea Therapeutics Stock Surging On Thursday?
KTTA

Benzinga

a year ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?

KTTA

MT Newswires

a year ago

Top Premarket Gainers

KTTA

MT Newswires

a year ago

Pasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety; Shares Rise Pre-Bell

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

Lotto 6/49 - $64 million up for grabs in the next draw!
KTTA

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
KTTA

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
KTTA

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
KTTA

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
KTTA

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
KTTA

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
KTTA

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
KTTA

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses
KTTA

Investor's Business Daily

a year ago

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library
KTTA

Business Wire

a year ago

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap
KTTA

Investor's Business Daily

a year ago

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

EnviroGold Global Closes First Tranche of Private Placement
KTTA

GlobeNewswire

a year ago

EnviroGold Global Closes First Tranche of Private Placement

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
KTTA

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

How markets digested hot jobs print: Top takeaways
KTTA

Yahoo Finance Video

a year ago

How markets digested hot jobs print: Top takeaways

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
KTTA

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"
KTTA

PR Newswire

a year ago

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
KTTA

GlobeNewswire

a year ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
KTTA

Business Wire

2 years ago

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

WYNNEFIELD CAPITAL IMPLORES TECHPRECISION TO GIVE ALL SHAREHOLDERS A VOICE IN VOTAW PRECISION TECHNOLOGIES TRANSACTION
KTTA

PR Newswire

2 years ago

WYNNEFIELD CAPITAL IMPLORES TECHPRECISION TO GIVE ALL SHAREHOLDERS A VOICE IN VOTAW PRECISION TECHNOLOGIES TRANSACTION

Educational Development Corporation (NASDAQ:EDUC) Q3 2024 Earnings Call Transcript
KTTA

Insider Monkey

2 years ago

Educational Development Corporation (NASDAQ:EDUC) Q3 2024 Earnings Call Transcript

Educational Development Corporation Announces Fiscal Third Quarter and Fiscal 2024 Year-to-Date Results
KTTA

Newsfile

2 years ago

Educational Development Corporation Announces Fiscal Third Quarter and Fiscal 2024 Year-to-Date Results

Kingstone CEO Letter to Shareholders
KTTA

ACCESSWIRE

2 years ago

Kingstone CEO Letter to Shareholders

bioAffinity Technologies In the News
KTTA

Business Wire

2 years ago

bioAffinity Technologies In the News

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Benson Hill Announces Gains in Soybean Breeding Program; Introduces Five 2024 Soybean Varieties Delivering Higher Protein and Improved Yield Potential
KTTA

Business Wire

2 years ago

Benson Hill Announces Gains in Soybean Breeding Program; Introduces Five 2024 Soybean Varieties Delivering Higher Protein and Improved Yield Potential

Tuttle Capital Management Launches 2x Inverse Regional Bank ETF
KTTA

GlobeNewswire

2 years ago

Tuttle Capital Management Launches 2x Inverse Regional Bank ETF

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

KULR Announces Closing of $1.035 Million All-Common Stock Public Offering, Including Full Exercise of Over-Allotment Option
KTTA

GlobeNewswire

2 years ago

KULR Announces Closing of $1.035 Million All-Common Stock Public Offering, Including Full Exercise of Over-Allotment Option

GEE Group, Inc. (AMEX:JOB) Q4 2023 Earnings Call Transcript
KTTA

Insider Monkey

2 years ago

GEE Group, Inc. (AMEX:JOB) Q4 2023 Earnings Call Transcript

Pasithea Therapeutics Announces Results from 2023 Annual Meeting
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Evaxion Announces Business Update and Third Quarter 2023 Financial Results
KTTA

GlobeNewswire

2 years ago

Evaxion Announces Business Update and Third Quarter 2023 Financial Results

Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 31%
KTTA

Simply Wall St.

2 years ago

Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 31%

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

DallasNews Corporation Announces First Quarter 2024 Dividend
KTTA

GlobeNewswire

2 years ago

DallasNews Corporation Announces First Quarter 2024 Dividend

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
KTTA

ACCESSWIRE

2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Closed-end funds advised by Allspring Funds Management renew share repurchase programs
KTTA

PR Newswire

2 years ago

Closed-end funds advised by Allspring Funds Management renew share repurchase programs

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript
KTTA

Insider Monkey

2 years ago

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript

Twin Vee Powercats Co. (NASDAQ:VEEE) Q3 2023 Earnings Call Transcript
KTTA

Insider Monkey

2 years ago

Twin Vee Powercats Co. (NASDAQ:VEEE) Q3 2023 Earnings Call Transcript

KTTA

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Twin Vee PowerCats Co Earnings Call

Twin Vee PowerCats Co. Reports an 8% Increase in Revenue for the Nine Months Ended September 30, 2023
KTTA

ACCESSWIRE

2 years ago

Twin Vee PowerCats Co. Reports an 8% Increase in Revenue for the Nine Months Ended September 30, 2023

KTTA

GlobeNewswire

2 years ago

Silver Spike Investment Corp. Reports Third Quarter 2023 Financial Results

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
KTTA

GlobeNewswire

2 years ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Benson Hill Announces Third Quarter 2023 Financial Results, Improves 2023 Outlook, and Pays Down Debt
KTTA

Business Wire

2 years ago

Benson Hill Announces Third Quarter 2023 Financial Results, Improves 2023 Outlook, and Pays Down Debt

YanGuFang Expands Whole Grain Food Offering On Leading E-Commerce Platforms
KTTA

GlobeNewswire

2 years ago

YanGuFang Expands Whole Grain Food Offering On Leading E-Commerce Platforms

Should You Invest in Seneca Foods Corporation (SENEA)?
KTTA

Insider Monkey

2 years ago

Should You Invest in Seneca Foods Corporation (SENEA)?

Share on Social Networks: